Person

Mark E. Bunnage

EVP, Chief Scientific Officer, Vertex Pharmaceuticals

Current S&P 500 boards
0
Current roles
1
Open-market buys
$0
Open-market sales
$3.0M

Current roles

From Section 16 filings (Forms 3, 4 and 5) in the last 13 months.

Past roles

“Last filing” is the latest Form 3/4/5 for that company, an upper bound on the end date.

None on record since 2016.

Sits alongside

People who currently share a board or management team with this person.

Open-market trades

Purchases and sales reported on Form 4 at S&P 500 companies.

DateCompanyTypeSharesPriceValue
May 15, 2026VRTXSale33$453.45$15K
Feb 25, 2026VRTXSale620$486.35$302K
Feb 18, 2026VRTXSale1,182$473.68$560K
Feb 17, 2026VRTXSale2,437$489.46$1.2M
Feb 11, 2026VRTXSale2,021$460.43$931K

SEC reporting-owner ID (CIK) 2100735 · all filings on EDGAR